3 Stocks Improving Performance Of The Health Care Sector

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 14,977 as of Monday, May 6, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,675 issues advancing vs. 1,221 declining with 157 unchanged.

The Health Care sector currently sits up 0.3% versus the S&P 500, which is up 0.2%. Top gainers within the sector include UnitedHealth Group ( UNH), up 3.0%, Humana ( HUM), up 3.0%, St Jude Medical ( STJ), up 2.7% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.8%. On the negative front, top decliners within the sector include Grifols ( GRFS), down 2.36, and Express Scripts ( ESRX), down 1.04.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector higher today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $1.94 (1.13) to $174.12 on light volume Thus far, 69,234 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 360,800 shares. The stock has ranged in price between $172.72-$174.12 after having opened the day at $173.47 as compared to the previous trading day's close of $172.18.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $94.8 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 5.5% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 2 analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Daily Earnings Round-Up

5 Things You Must Know Before the Market Opens Wednesday